Diagram is your expert in supporting cardiovascular research. Every clinical scientific research project is unique and deserves a customized approach! Schedule your appointment in advance and contact us!
The final one and two year results of the REDUCE trial have been presented as Late Breaking Trial by prof. Giuseppe De Luca at the EuroPCR congres in Paris.
According to the results of the DAPA trial, prophylactic implantation of an implantable cardioverter defibrillator within 90 days in patients with STEMI undergoing PCI reduced the risk for death in certain high-risk patients.
Recently, the audit took place at Diagram for the recertification of our ISO 9001:2015 quality management system. We are proud to announce that our ISO certificate has been extended until September 22, 2021.
In order to perform clinical research several laws and regulations need to be followed. The requirements for the research team and especially the investigator have been sharpened.
Myocardial infarction patients who undergo percutaneous coronary intervention and stenting do not have more adverse events at 3 months than at 12 months of dual antiplatelet therapy. This is the main finding of the REDUCE trial which was presented by prof. Harry Suryapranata (Radboudumc) during the TCT congress in Denver.
